Literature DB >> 17165325

Assessing the willingness of parents to pay for reducing postoperative emesis in children.

L Diez1.   

Abstract

This study assessed the willingness of parents to pay for a reduction in the postoperative emesis experienced by children. The willingness-to-pay technique was used to value the intangible benefits, such as relief from anxiety and discomfort, resulting from a reduction in postoperative emesis in children; anxiety and discomfort are currently excluded from most cost-effectiveness studies of antiemetic agents. A structured questionnaire was used to interview a representative sample of 162 parents. These were parents, identified by Gallup, whose children had undergone surgery within the previous 2 years and, therefore, were familiar with the postoperative experience. The median willingness to pay for a reduction in postoperative emesis in children was found to be 50 pounds sterling (30% of parents were unwilling to pay more than 5 pounds sterling, while more than 35% of parents were willing to pay 100 pounds sterling or more). Most parents expressed some degree of worry about postoperative nausea and vomiting; 24% were very worried about it. This study found that simple cost-effectiveness studies of antiemetic agents including only direct costs underestimate the true value of the intervention.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 17165325     DOI: 10.2165/00019053-199813050-00011

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  11 in total

1.  Assessing the economic value of a new antidepressant. A willingness-to-pay approach.

Authors:  B J O'Brien; S Novosel; G Torrance; D Streiner
Journal:  Pharmacoeconomics       Date:  1995-07       Impact factor: 4.981

Review 2.  Economic evaluation of osteoporosis prevention.

Authors:  M Johannesson; B Jönsson
Journal:  Health Policy       Date:  1993-05       Impact factor: 2.980

3.  Stepwise or couple antenatal carrier screening for cystic fibrosis?: women's preferences and willingness to pay.

Authors:  Z Miedzybrodzka; J Semper; P Shackley; M Abdalla; C Donaldson
Journal:  J Med Genet       Date:  1995-04       Impact factor: 6.318

4.  Risk reduction from low osmolality contrast media. What do patients think it is worth?

Authors:  L J Appel; E P Steinberg; N R Powe; G F Anderson; S A Dwyer; R R Faden
Journal:  Med Care       Date:  1990-04       Impact factor: 2.983

5.  A double-blinded comparison of metoclopramide and droperidol for prevention of emesis following strabismus surgery.

Authors:  D M Lin; S R Furst; A Rodarte
Journal:  Anesthesiology       Date:  1992-03       Impact factor: 7.892

6.  Prophylactic antiemetic treatment with ondansetron in children undergoing tonsillectomy.

Authors:  S R Furst; A Rodarte
Journal:  Anesthesiology       Date:  1994-10       Impact factor: 7.892

7.  Postoperative emesis following otoplasty in children.

Authors:  D Paxton; R H Taylor; T M Gallagher; P M Crean
Journal:  Anaesthesia       Date:  1995-12       Impact factor: 6.955

8.  Pediatric anesthesia morbidity and mortality in the perioperative period.

Authors:  M M Cohen; C B Cameron; P G Duncan
Journal:  Anesth Analg       Date:  1990-02       Impact factor: 5.108

9.  The antiemetic effect of droperidol following outpatient strabismus surgery in children.

Authors:  M D Abramowitz; T H Oh; B S Epstein; U E Ruttimann; D S Friendly
Journal:  Anesthesiology       Date:  1983-12       Impact factor: 7.892

10.  Effect of antiemetic therapy on recovery and hospital discharge time. A double-blind assessment of ondansetron, droperidol, and placebo in pediatric patients undergoing ambulatory surgery.

Authors:  P J Davis; F X McGowan; I Landsman; K Maloney; P Hoffmann
Journal:  Anesthesiology       Date:  1995-11       Impact factor: 7.892

View more
  9 in total

Review 1.  A 'league table' of contingent valuation results for pharmaceutical interventions: a hard pill to swallow?

Authors:  Tracey H Sach; Richard D Smith; David K Whynes
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 2.  Therapeutic options for the prevention and treatment of postoperative nausea and vomiting: a pharmacoeconomic review.

Authors:  Jean Lachaine
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 3.  Ondansetron: a review of its use as an antiemetic in children.

Authors:  C R Culy; N Bhana; G L Plosker
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

4.  Perspectives toward oral mucositis prevention from parents and health care professionals in pediatric cancer.

Authors:  Marie-Chantal Ethier; Dean A Regier; Deborah Tomlinson; Peter Judd; John Doyle; Adam Gassas; Ahmed Naqvi; Lillian Sung
Journal:  Support Care Cancer       Date:  2011-09-25       Impact factor: 3.603

5.  Willingness-to-pay to avoid the time spent and discomfort associated with screening colonoscopy.

Authors:  Daniel E Jonas; Louise B Russell; Jon Chou; Michael Pignone
Journal:  Health Econ       Date:  2010-10       Impact factor: 3.046

Review 6.  Anesthesia for ORL surgery in children.

Authors:  Karin Becke
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2014-12-01

7.  Aromatherapy for the treatment of PONV in children: a pilot RCT.

Authors:  Mathew B Kiberd; Suzanne K Clarke; Jill Chorney; Brandon d'Eon; Stuart Wright
Journal:  BMC Complement Altern Med       Date:  2016-11-09       Impact factor: 3.659

8.  Assessment of Dog Owner Concern Regarding Peri-operative Nausea and Vomiting and Willingness to Pay for Anti-emetic Treatment.

Authors:  Bonnie L Hay Kraus; Callie Cazlan
Journal:  Front Vet Sci       Date:  2019-08-22

9.  Incidence, characteristics and risk factors of adverse drug reactions in hospitalized children - a prospective observational cohort study of 6,601 admissions.

Authors:  Signe Thiesen; Elizabeth J Conroy; Jennifer R Bellis; Louise E Bracken; Helena L Mannix; Kim A Bird; Jennifer C Duncan; Lynne Cresswell; Jamie J Kirkham; Matthew Peak; Paula R Williamson; Anthony J Nunn; Mark A Turner; Munir Pirmohamed; Rosalind L Smyth
Journal:  BMC Med       Date:  2013-11-07       Impact factor: 8.775

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.